|
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): 9 Month figures/9 Month figures
Corporate News Bad Neustadt a. d. Saale | 9 November 2023
RHÖN-KLINIKUM AG increases consolidated profit and revenues
The increase in materials and consumables used of 30.6 million euros or 9.3 per cent was disproportionate to the rise in revenues due to higher purchasing prices. From January to September 2023 a total of 664,594 patients were treated on an inpatient and outpatient basis in the hospitals and medical care centres, 3.6% more compared with the same period of the previous year (9M 2022: 641,622). “The first nine months of financial year 2023 at RHÖN-KLINIKUM AG continued to be characterized by the considerable uncertainties in connection with geopolitical risks and their effects, rising energy and commodity prices and the associated high, albeit declining, level of inflation. Our attention was also focused on the impending hospital reform the specific impacts of which are not yet foreseeable at this time. However, we believe the position of our hospitals makes us well prepared for that”, said Stefan Stranz, CFO of RHÖN-KLINIKUM AG.
For the current financial year 2023, RHÖN-KLINIKUM AG continues to expect revenues of 1.5 billion euros within a range of +/- 5 per cent. For earnings before interest, tax and depreciation/amortisation (EBITDA), we continue to expect a level of between 103 million euros and 109 million euros. It should be noted that the outlook is subject to considerable uncertainties in connection with the geopolitical risks and their impacts, the effects of inflation on cost development, the macroeconomic environment and any regulatory measures affecting our remuneration structure in 2023. Full results are published in the Quarterly Statement at:
RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations & Sustainability
09.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | RHÖN-KLINIKUM Aktiengesellschaft |
| Salzburger Leite 1 | |
| 97616 Bad Neustadt a.d.Saale | |
| Germany | |
| Phone: | +49 (0)9771 - 65-0 |
| Fax: | +49 (0)9771 - 97 467 |
| E-mail: | rka@rhoen-klinikum-ag.com |
| Internet: | www.rhoen-klinikum-ag.com |
| ISIN: | DE0007042301 |
| WKN: | 704230 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1769009 |
| End of News | EQS News Service |
|
|
1769009 09.11.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
